SSA001 Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    Sino Biological goat anti human igg fc secondary antibody
    Study design and clinical measures of HEV vaccine response. a Immunization regimen and critical time points in the longitudinal analysis of human B-cell response to the HEV vaccine, Hecolin ® . The first, second, and third doses are indicated above the time axis at days 0, 31, and 183, respectively, with black arrows and needles. The seven time points selected for antibody-repertoire sequencing are indicated below the time axis with red arrows and “NGS.” Vaccine-induced, p239(1)-specific monoclonal antibodies (mAbs) were isolated from samples collected 1 month after the third dose (3M1), which is labeled below the time axis. Dynamics of anti-HEV <t>IgG</t> titer ( b ), anti-HEV IgG avidity ( c ), and serum neutralization measured by the 50% inhibitory dose (ID 50 ) ( d ) during vaccination. Error bars indicate standard deviation (s.d.) in ( b ). The dash lines represent the detection limit for the anti-HEV IgG and the threshold of neutralizing capacity for the serum neutralization assays. *Only anti-HEV IgG positive sera were tested for anti-HEV IgG avidity. Source data are provided in the Source Data file.
    Goat Anti Human Igg Fc Secondary Antibody, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/goat anti human igg fc secondary antibody/product/Sino Biological
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    goat anti human igg fc secondary antibody - by Bioz Stars, 2021-07
    94/100 stars
      Buy from Supplier

    Image Search Results


    Study design and clinical measures of HEV vaccine response. a Immunization regimen and critical time points in the longitudinal analysis of human B-cell response to the HEV vaccine, Hecolin ® . The first, second, and third doses are indicated above the time axis at days 0, 31, and 183, respectively, with black arrows and needles. The seven time points selected for antibody-repertoire sequencing are indicated below the time axis with red arrows and “NGS.” Vaccine-induced, p239(1)-specific monoclonal antibodies (mAbs) were isolated from samples collected 1 month after the third dose (3M1), which is labeled below the time axis. Dynamics of anti-HEV IgG titer ( b ), anti-HEV IgG avidity ( c ), and serum neutralization measured by the 50% inhibitory dose (ID 50 ) ( d ) during vaccination. Error bars indicate standard deviation (s.d.) in ( b ). The dash lines represent the detection limit for the anti-HEV IgG and the threshold of neutralizing capacity for the serum neutralization assays. *Only anti-HEV IgG positive sera were tested for anti-HEV IgG avidity. Source data are provided in the Source Data file.

    Journal: Nature Communications

    Article Title: Quantitative evaluation of protective antibody response induced by hepatitis E vaccine in humans

    doi: 10.1038/s41467-020-17737-w

    Figure Lengend Snippet: Study design and clinical measures of HEV vaccine response. a Immunization regimen and critical time points in the longitudinal analysis of human B-cell response to the HEV vaccine, Hecolin ® . The first, second, and third doses are indicated above the time axis at days 0, 31, and 183, respectively, with black arrows and needles. The seven time points selected for antibody-repertoire sequencing are indicated below the time axis with red arrows and “NGS.” Vaccine-induced, p239(1)-specific monoclonal antibodies (mAbs) were isolated from samples collected 1 month after the third dose (3M1), which is labeled below the time axis. Dynamics of anti-HEV IgG titer ( b ), anti-HEV IgG avidity ( c ), and serum neutralization measured by the 50% inhibitory dose (ID 50 ) ( d ) during vaccination. Error bars indicate standard deviation (s.d.) in ( b ). The dash lines represent the detection limit for the anti-HEV IgG and the threshold of neutralizing capacity for the serum neutralization assays. *Only anti-HEV IgG positive sera were tested for anti-HEV IgG avidity. Source data are provided in the Source Data file.

    Article Snippet: The membranes were blocked with 5% skim milk and then incubated with sera or p239(1)-specific mAbs for 30 min. After rinse, the membranes were incubated with anti-human HRP-conjugated antibody (Sino Biological inc, Cat# SSA001).

    Techniques: Sequencing, Isolation, Labeling, Neutralization, Standard Deviation

    PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cell lines (A ) T47D and MDA-MB-231 cells were treated with 75ng/ml IFN-γ for 24 hours and the cell surface expression of PD-L1 was determined by flow cytometry. The shaded histograms indicate staining with PE-labeled isotype control IgG, the dashed histograms indicate staining with PE-labeled anti-PD-L1 antibody, and the open histograms indicate IFN-γ treated cells staining with PE-labeled anti-PD-L1 antibody. ( B ) MDR1 mRNA was analyzed by real-time quantitative PCR in MDA-MB-231 cells or IFN-γ-treated T47D cells after treatment with IgG Fc or PD-1-Fc for 24 h. Amplification of β-actin mRNA was used as a control.( * p

    Journal: Oncotarget

    Article Title: PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways

    doi: 10.18632/oncotarget.21914

    Figure Lengend Snippet: PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cell lines (A ) T47D and MDA-MB-231 cells were treated with 75ng/ml IFN-γ for 24 hours and the cell surface expression of PD-L1 was determined by flow cytometry. The shaded histograms indicate staining with PE-labeled isotype control IgG, the dashed histograms indicate staining with PE-labeled anti-PD-L1 antibody, and the open histograms indicate IFN-γ treated cells staining with PE-labeled anti-PD-L1 antibody. ( B ) MDR1 mRNA was analyzed by real-time quantitative PCR in MDA-MB-231 cells or IFN-γ-treated T47D cells after treatment with IgG Fc or PD-1-Fc for 24 h. Amplification of β-actin mRNA was used as a control.( * p

    Article Snippet: Cells were supplemented with human recombinant PD-1-Fc (1 μg/ml for T47D cells, and 0.5 μg/ml for MDA-MB-231 cells, Genscript) or IgG Fc (Sino Biological) for 24 h and harvested for further analysis.

    Techniques: Expressing, Multiple Displacement Amplification, Flow Cytometry, Staining, Labeling, Real-time Polymerase Chain Reaction, Amplification

    Effect of PD-1/PD-L1 interaction on phosphorylated ERK (p-ERK) and phosphorylated AKT (p-AKT) in MDA-MB-231 ( A ) p-RRK and total ERK were determined by western blot after treatment with IgG Fc or PD-1-Fc for indicated periods. ( B ) p-AKT and total AKT were determined by western blot after treatment with IgG Fc or PD-1-Fc for indicated periods. Numbers represent p-ERK or pAKT relative signal intensities.

    Journal: Oncotarget

    Article Title: PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways

    doi: 10.18632/oncotarget.21914

    Figure Lengend Snippet: Effect of PD-1/PD-L1 interaction on phosphorylated ERK (p-ERK) and phosphorylated AKT (p-AKT) in MDA-MB-231 ( A ) p-RRK and total ERK were determined by western blot after treatment with IgG Fc or PD-1-Fc for indicated periods. ( B ) p-AKT and total AKT were determined by western blot after treatment with IgG Fc or PD-1-Fc for indicated periods. Numbers represent p-ERK or pAKT relative signal intensities.

    Article Snippet: Cells were supplemented with human recombinant PD-1-Fc (1 μg/ml for T47D cells, and 0.5 μg/ml for MDA-MB-231 cells, Genscript) or IgG Fc (Sino Biological) for 24 h and harvested for further analysis.

    Techniques: Multiple Displacement Amplification, Western Blot